

2. On page 36, at the end of the specification and before the Claims, please insert the printed Sequence Listing submitted concurrently herewith, and renumber page 1 of the Sequence Listing as page 37 of the specification.

## IN THE CLAIMS

Please cancel claims 2-20, without prejudice or disclaimer, and kindly add the following claims:

34. (New) The composition according to claim 1, wherein said composition is a feed.

35. (New) The composition according to claims 1, wherein said composition contains no anti-infection agent other than said enzyme.

36. (New) The composition according to claim 1, wherein said enzyme cleaves a linkage that effects release of a cell-surface protein.

37. (New) The composition according to claim 1, wherein said enzyme is selected from the group consisting of esterases, cerebrosidases, and carbohydrases that cleave a linkage that effects release of a cell-surface protein or carbohydrate.

38. (New) The composition according to claim 37, wherein said esterases are selected from the group consisting of sphingomyelinases and phospholipases.

39. (New) The composition according to claim 38, wherein said phospholipase is a type C or type D phospholipase.

40. (New) The composition according to claim 38, wherein said phospholipase is a phosphatidylinositol-specific phospholipase C.

41. (New) The composition according to claim 1, wherein said composition further comprises a stabilizer, a carbohydrate carrier or a preservative.

42. (New) The composition according to claim 41, wherein said stabilizer is a buffer, a carbohydrate or a glycol.

43. (New) The composition according to claim 41, wherein said carbohydrate carrier is selected from the group consisting of xylose, fructose, glucose, sorbitol, and maltotriose.

44. (New) The composition according to claim 41, wherein said preservative is selected from the group consisting of propylparaben, sodium sorbate, potassium sorbate, and ascorbyl palmitate.

45. (New) The composition according to claim 1, wherein said carrier is a foodstuff into which said enzyme is incorporated.

46. (New) The composition according to anyone of claim 45, wherein said foodstuff is an animal feed comprised of grain material, a source of protein, vitamins, amino acids, and minerals.

47. (New) The composition according to claim 46, wherein said grain material is corn, sorghum, wheat, barley or oats.

*A4*  
48. (New) The composition according to claim 46, wherein said source of protein is beans or peas.

49. (New) The composition according to claim 1, wherein said composition is in a solid or a liquid formulation.

50. (New) The composition according to claim 1, wherein said enzyme is contained in a tablet or a gelatin capsule shell.

51. (New) The composition according to claim 1, wherein said enzyme is prepared from a *Bacillus cereus* strain.

52. (New) The composition according to claim 51, wherein said *Bacillus cereus* strain is ATCC 7004 or ATCC 6464.

53. (New) The composition according to claim 1, wherein said enzyme is obtained by expression of a recombinant DNA in a host organism.

54. (New) The composition according to claim 53, wherein said host organism is from a *Bacillus megaterium* strain.

55. (New) The composition according to claim 1, wherein said enzyme is present at 200 IU/Kg -4000 IU/Kg feed.

56. (New) The composition according to claim 32, wherein said carrier is a foodstuff into which said enzyme is incorporated.

57. (New) The composition according to claim 56, wherein said foodstuff is an animal feed comprised of grain material, a source of protein, vitamins, amino acids, and minerals.

58. (New) The composition according to claim 57, wherein said grain material is corn, sorghum, wheat, barley or oats.

59. (New) The composition according to claim 57, wherein said source of protein is beans or peas.

60. (New) The composition according to claim 32, wherein said composition is in a solid or a liquid formulation.

61. (New) The composition according to claim 32, wherein said enzyme is contained in a tablet or gelatin capsule shell.

62. (New) The composition according to claim 32, wherein said enzyme is a hemicellulase.

63. (New) The composition according to claim 62, wherein said hemicellulase is a mannanase.

64. (New) The composition according to claim 63, wherein said mannanase is the endo-1,4- $\beta$ -D-mannanase produced by *Bacillus lentus* designated as ATCC 55045.

65. (New) The composition according to claim 32, wherein said enzyme is selected from the group consisting of esterases, cerebrosidases, and carbohydrases that cleave a linkage that effects release of a cell-surface protein or carbohydrate.

66. (New) The composition according to claim 65, wherein said esterases are selected from the group consisting of sphingomyelinases and phospholipases.

67. (New) The composition according to claim 66, wherein said phospholipase is a type C or a type D phospholipase.

68. (New) The composition according to claim 66, wherein said phospholipase is a phosphatidylinositol-specific phospholipase C.

69. (New) The composition according to claim 32, wherein said composition further comprises a stabilizer, a carbohydrate carrier or a preservative.

70. (New) The composition according to claim 69, wherein said stabilizer is a buffer, a carbohydrate or a glycol.

*Q4*  
71. (New) The composition according to claim 69, wherein said carbohydrate carrier is selected from the group consisting of xylose, fructose, glucose, sorbitol, and maltotriose.

72. (New) The composition according to claim 69, wherein said preservative is selected from the group consisting of propylparaben, sodium sorbate, potassium sorbate, and ascorbyl palmitate.

---

#### REMARKS

Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and the following comments.

Claims 1-33 are pending. Claims 2-20 are cancelled, without prejudice to or disclaimer of the claimed subject matter. New claims 34-72 are added to clearly set forth the nature of the claimed invention. New claims 41-44 and 69-72 are added to include the additional components that clearly typify a therapeutic composition that the cited documents do not teach. Support for this amendment is found throughout the specification, in particular, at page 12, line 1 to page 13, line 16. Another set of new claims (37-40 and 65-68), directed to esterases, is inserted. This amendment is supported throughout the entire specification, particularly at pages 14-25. Accordingly, claims 1, 32, and 34-76 are pending. These amendments do not go beyond the original disclosure of the application.

#### *Sequence Compliance*

Applicants have inserted the sequence identification numbers for two oligonucleotide sequences that are described on page 18, lines 7 and 8.

In accordance with the requirements of 37 C.F.R. § 1.821 through 1.825, a paper copy of the Sequence Listing, together with a copy of the Sequence Listing in computer readable form, are submitted herewith.

#### *Claim Objections*

Cancellation of claims 10 and 14-15 has rendered the objection of these claims moot. Thus, withdrawal of this objection is earnestly requested.